Mr Adam  S Heterick, B.AppSci (Biotech) M. Bioinformatics

Indigenous Bioinformatician, Black Ochre Data Labs (The Kids Research Institute Australia & Australian National University)

Adam Heterick is a Wiradjuri bioinformatician and Australia's first Indigenous bioinformatician, with expertise in pharmacogenomics, Indigenous data sovereignty and the translation of genomic research into equitable health outcomes. His work focuses on ensuring that advances in precision health reach Aboriginal and Torres Strait Islander peoples and other historically underserved populations through technically rigorous, community-governed approaches to genomic data.

As an Early Career Researcher with the Lancet Commission on Precision Health, Adam brings expertise in bioinformatics, Indigenous data governance (ID-Sov/ID-Gov) and the infrastructure that makes precision health equitable in practice. Through his role at Black Ochre Data Labs and through his appointment at the National Centre for Indigenous Genomics at the Australian National University, he works at the intersection of large-scale genomics and Indigenous data governance. He serves on the NHMRC-MRFF Joint Indigenous Advisory and Consumer Advisory Groups, informing national research policy, and co-leads data management for the Canadian Marine Biomass Innovation initiative, developing Indigenous data sovereignty systems at scale. His combination of frontline bioinformatics capability and governance expertise ensures that the Commission's frameworks are grounded in what is technically achievable as well as ethically sound, and that the data foundations underpinning precision health are built to serve diverse populations rather than replicate existing inequities.

Ms. Arabella R Hart, B.Pharm (Hons)

Program Coordinator, Walter And Eliza Hall Institute Of Medical Research, Melbourne, Victoria Australia

Arabella Hart is an early career researcher and clinical pharmacist with expertise in Indigenous genomics, medicine access and health system equity. A proud Aboriginal woman, Arabella’s research focuses on advancing equitable access to genomic care for Aboriginal and Torres Strait Islander peoples through Indigenous-led approaches to research, policy and healthcare delivery.

As an Early Career Researcher with the Lancet Commission on Precision Health, Arabella brings expertise in Indigenous governance, community engagement and the implementation of culturally safe precision health initiatives. She has led Indigenous-governed genomics programs through the Australian Alliance for Indigenous Genomics (ALIGN) Victoria, contributed to Cancer Australia's National Framework for Genomics in Cancer Control and helped advance Indigenous Genomic Data Sovereignty initiatives across Australia. Her connections with Aboriginal and Torres Strait Islander community-controlled health organisations, communities, health services, researchers and policymakers ensure that Indigenous perspectives, priorities and leadership are meaningfully represented in and influence discussions on the future of precision health.

Dr Carolyn Wai Ling Chee, PhD

Consultant Physician and Endocrinologist,  Medical Lecturer Department of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia

Dr Carolyn Chee is a Consultant Physician, Endocrinologist and Medical Lecturer at the Universiti of Malaya. She graduated from the University of Manchester and completed her specialist training in Diabetes, Endocrinology and General Internal Medicine in the East Midlands, United Kingdom. She  obtained a PhD in Nutrition and Metabolism and a Master of Medical Education (MMedSci) from the University of Nottingham.

Dr Carolyn Chee brings with her 20 years of UK clinical experience prior to returning to Malaysia in 2026. She was a Consultant Endocrinologist at Nottingham University Hospitals NHS Trust, where she provided clinical leadership across clinical diabetes research, undergraduate medical education, governance, stewardship and strategic steering groups. She was obesity lead in the Trust’s Health Improvement Steering Group incorporating preventive health strategies. She has chaired several National Diabetes and Technology Network Forums in the U.K.

As a Fellow of the Royal College of Physicians (London), Dr Carolyn Chee is passionate about advancing excellence in medical education, leadership development, clinical governance and patient-centred care.

Prof. Siyang Liu, MSc, PhD

Associate Professor of Statistical Genetics and Biomedical Informatics, Zhongshan School of Medicine, Sun Yat-sen University

Dr. Siyang Liu, MSc, PhD, is a tenured Associate Professor of Statistical Genetics and Biomedical Informatics at Zhongshan School of Medicine, Sun Yat-sen University, and one of the Co-Chairs of the Working Group on Data and Translational Research (Study Design, Analysis, and Benchmarking) for The Lancet Commission on Global Implementation of Precision Health. Her research integrates statistical genetics, bioinformatics, artificial intelligence, and causal inference to elucidate the genetic and environmental determinants of disease, inform mechanistic investigations, and facilitate the translation of precision-health innovations into clinical and public health practice. She leads MONN, a large-scale maternal and child health initiative linking clinically generated genomic sequencing data with longitudinal electronic health records from more than half a million individuals in China. MONN drives methodological innovation and provides unique data resources for investigating the developmental origins of health and disease across the life course and informing targeted intervention strategies. As a (co-)first or corresponding author, she has published influential research in leading journals, including Cell, Nature, Nature Genetics,  Journal of Hepatology, Blood, Nature Communications, and EClinicalMedicine. She brings to the Commission expertise in generating robust biological and clinical evidence through innovative study designs that integrate large-scale healthcare and multi-omics data, as well as in advancing the equitable implementation of precision health across diverse populations and healthcare systems.

Dr. Marjan Walli-Attaei, PhD

Senior Researcher, Nuffield Department of Primary Care Health Sciences, University of Oxford

Precision health arrives into systems that are already unequal, and whether it narrows those inequalities or widens them will depend on how it is paid for and delivered. I am a health economist working across health systems, global cardiovascular epidemiology, and economic evaluation, and I can help the Commission establish whether precision health can be afforded, delivered, and distributed fairly at every income level, not only the wealthiest.

Most of my work is comparative across countries, since precision derived in one population is not automatically portable to another. My first-author work in The Lancet, The Lancet Global Health, and The Lancet Public Health has drawn on the largest global cohorts and registries available, spanning up to 40 countries, to show how risk, treatment, and outcomes diverge between women and men and between rich and poor settings, and how the availability and affordability of even basic medicines governs who benefits from clinical advance. A treatment correctly identified and unobtainable leaves the patient no better off.

I also work on health-related quality of life, measures already used to decide what health systems will pay for and among the few standardised ways to ask whether precision health delivers benefit patients recognise. In collaboration with the European Society of Cardiology, I contribute to a programme costing cardiovascular disease across the European Union, work that helped make the economic case for the EU's Safe Hearts plan and now continues as a modelling exercise to advise concretely on which policies and interventions member states should adopt.

Dr. Wei Zhou, PhD

Assistant Researcher, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine 

Dr. Wei Zhou, PhD, is an Assistant Researcher at Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, and an Early Career Researcher (ECR) in Group 3 of The Lancet Commission on Precision Health. His research centres on the mechanisms and pharmacogenomics of neuropsychiatric disorders—such as autism spectrum disorder—and birth defects—such as congenital heart disease—where he has identified multiple molecular markers specific to Chinese populations and developed associated patents. As a (co-)first or corresponding author he has published more than 20 SCI papers in leading journals including Signal Transduction and Targeted Therapy, Science Bulletin, Molecular Psychiatry, Environmental International, CNS Neuroscience & Therapeutics, and Frontiers in Pharmacology, with over 4,666 citations and an H-index of 15. He has contributed chapters to several monographs, including Pharmacogenomics in Precision Medicine (Springer), and has participated in large international consortia such as the Psychiatric Genomics Consortium. As Principal Investigator he leads a National Natural Science Foundation Young Scientists Fund project on pharmacogenetic markers for autism therapeutics and contributes to National Key R&D Programs on the neurogenetics of autism and on preimplantation genetic diagnosis. He brings to the Commission expertise in translating multi-omics and pharmacogenomic discovery into precision-health applications for diverse populations, and in advancing the equitable implementation of precision medicine through nationally funded, population-specific research.

Dr. Zahra Haider PhD

Research Specialist, Karolinska Institutet, Stockholm, Sweden 

I bring to The Lancet Commission on Precision Health more than a decade of experience in translational cancer research, with a particular focus on developing and implementing precision diagnostic approaches for cancer management. Originally from Pakistan, I moved to Sweden for postgraduate training in molecular biology and subsequently completed a PhD in Medical Science with a specialization in cancer pathology at Umeå University. Following postdoctoral training in clinical cancer genetics and translational research, I currently hold research positions at Karolinska Institutet in Sweden and University Hospital Heidelberg in Germany. My research work has focused on the development and implementation of innovative, high-throughput, clinically feasible molecular tools and computational workflows that significantly advance diagnostic classification, patient risk
stratification, and early detection of treatment resistance and relapse in cancer management. I actively contribute to Genomic Medicine Sweden, Sweden’s national initiative for advancing precision medicine and integrating genomic approaches into healthcare, while also engaging in teaching, scientific communication and public outreach.

A central perspective I bring to the Commission is the need to ensure that advances in precision health translate into meaningful and equitable benefits across diverse health systems and economic settings. My scientific experience, combined with my personal and professional connections to both high-resource and resource-constrained contexts, motivates my focus on how advanced diagnostic technologies can be adapted and implemented sustainably rather than remaining concentrated in well-resourced health systems. Within the Commission, I contribute particularly to work evaluating the landscape and readiness of precision health infrastructure across different economies, as well as assessing the costs of action and inaction towards implementing precision health approaches. Through this work, I aim to help develop practical, evidence-based roadmaps for precision health implementation that account for technological capability, clinical utility, affordability, and local health-system realities, ultimately helping ensure that precision health advances reduce, rather than widen, existing global health inequities.

Allison Y Ebsen, BSc

PhD Student at Nanyang Technological University Singapore

Allison is a PhD researcher in Medicine whose work examines the interconnectedness of environmental and population health, with a focus on how the environments in which people live shape health outcomes. With a background in Computer Science, Allison brings a technical, multidisciplinary approach that connects computational methods with medical, environmental, and population-health perspectives. Research experience at the Broad Institute, alongside experiences studying and engaging with diverse communities in Hawaii, has broadened her perspective on complex health questions and strengthened her appreciation of the biological, environmental, and social contexts that shape health. Motivated by a strong sense of purpose and service, she is committed to applying her technical and interdisciplinary training to complex health challenges in pursuit of meaningful and equitable impact. She brings a systems-oriented perspective on how precision health can account for the broader contexts that shape health across populations and settings.

Dr. Liang Yao, PhD

Assistant Professor & Nanyang Technological University Singapore 

Dr. Yao is a health research specialist with a Ph.D. from McMaster University, where he honed his expertise in health research methodologies. His academic focus encompasses several areas, including evidence synthesis (such as meta-analysis and network meta-analysis), guideline development, evidence certainty assessment using the GRADE framework.

Dedicated to enhancing patient outcomes and quality of life, Dr. Yao's research aims to translate robust clinical evidence into actionable practice guidelines. He is particularly passionate about integrating artificial intelligence technologies to streamline evidence synthesis and guideline development processes and increase the efficiency and impact of translating complex evidence into practical, trustworthy guidelines that can be readily adopted in clinical settings.

Dr. Yao continues to push the boundaries of health research, striving to create a seamless connection between rigorous scientific evidence and everyday medical practice. His commitment to excellence and innovation ensures that his work not only contributes to academic discourse but also makes a tangible difference in patient care and public health.

Dr. Mathangi Palanivel , PhD

Post-Doctoral Research Fellow at the Lee Kong Chian School of Medicine

Dr. Mathangi Palanivel is a Post-Doctoral Research Fellow at the Lee Kong Chian School of Medicine, working under Professor Sanjay H. Chotirmall in the Translational Respiratory Research Laboratory. Her Ph.D. in Medicine (Neuroscience), also from LKCMedicine, centred on nanoparticles targeting α-synuclein aggregation in Parkinson's disease, where she designed graphene quantum dots as theranostic agents — published in journals including RSC Advances, npj Parkinson's Disease, and RSC Chemical Communications, and giving her a strong grounding in nanotechnology, disease-mechanism discovery, and advanced imaging.

This training in assay design and disease-signature validation now supports her work with patient-derived human nasal epithelial cell (HNEC) lines, alongside emerging work in characterizing disease signatures through sequencing, and analysing microbiome data in large pulmonary disease cohorts. Her evidence-synthesis work further strengthens her ability to critically evaluate findings across clinical, molecular, and microbiome data, supporting her goal of pairing experimental rigor with multi-omics approaches to identify actionable, patient-specific molecular markers.

This opportunity will broaden her scientific network and expose her to collaborations that can refine her research direction, deepening her understanding of how multi-omics and systems biology are shaping respiratory diagnosis and therapy, and helping connect her wet-lab background to translational frameworks for patient stratification and personalized care.

Dr. Mi Huang, PhD

Faculty Member, School of Pharmaceutical Sciences, South-Central Minzu University, China

Dr. Mi Huang is a researcher in pharmacology and metabolic disease with expertise in precision medicine, human genetics, functional genomics, and experimental pharmacology. He received his PhD from Lund University, Sweden, where his research focused on the molecular and genetic mechanisms underlying metabolic diseases. His current work integrates human genetic evidence with CRISPR-based functional genomics, multi-omics, and cellular and animal models to identify and validate disease mechanisms and therapeutic targets, particularly in obesity and type 2 diabetes.

Within the Lancet Commission on Precision Health, Dr. Huang brings expertise in bridging population-level genetic evidence with mechanistic and translational research. His experience across research environments in China and Sweden also provides an international perspective on translating precision-health discoveries into biologically informed strategies for the prevention and treatment of cardiometabolic diseases.

Thandeka V.B. Malinga, BSc, BHSc (Hons), MSc (Med)

PhD Student, Sydney Brenner Institute for Molecular Bioscience, University of the Witwatersrand 

As an Early Career Researcher specializing in genomics and pharmacogenomics, I bring an African population perspective to The Lancet Commission on Precision Health and its working group on Governance, Accountability, and Authority. Africa holds the world's highest human genetic diversity, yet it remains underrepresented in global genomic data. Establishing fair, transparent, and robust governance is critical to ensure precision health strategies narrow global health inequities rather than widen them. My work centres on assessing and offering recommendations on data sovereignty, regulatory frameworks, and decision-making models across diverse health settings, ensuring data is managed responsibly while remaining practically useful in the clinic.

Through the Commission, I evaluate how global governance frameworks can be adapted to respect local healthcare authority, regulatory needs, and community priorities. Collaborating across the Commission’s multidisciplinary network, I work to bridge the gap between research and real-world application; helping define clear, accountable paths for integrating health data into everyday healthcare. Bringing grounded insights on regional health system readiness and resource realities, I help ensure the Commission develops governance models that are ethically sound, globally inclusive, and actionable on the ground.

Dr. Claudia Buchweitz, PhD

Researcher, Hospital Moinhos De Vento, Porto Alegre, Brazil

Claudia Buchweitz, PhD, is a researcher at the Mental Health Research Unit of Hospital Moinhos de Vento and with the Child and Adolescent Depression Program (Prodia), Brazil. Her work lies at the intersection of developmental epidemiology, population mental health, and risk stratification. She was a member of the lead writing group of the Lancet–World Psychiatric Association Commission on Depression and contributed to the background evidence for UNICEF’s first flagship report devoted to children’s mental health. In 2020, she was named an honorary member of the World Psychiatric Association. 

Dr. Buchweitz brings to the Lancet Commission on Precision Health a perspective grounded in the realities of diverse populations and health systems, particularly in Brazil. Her experience encompasses research design and interpretation, international scientific publishing, cross-institutional collaboration, and evidence dissemination. This combination will enable her to contribute to end-to-end evaluations of precision-health approaches—from risk assessment and data analysis to benchmarking, cost considerations, care delivery, and equitable implementation—and to help ensure that methodological advances translate into practicable, context-sensitive improvements in health care.

Dr. Jessica A. Lindberg, MD

PhD Student, Lecturer in Evidence-Based Medicine, Umeå University 

Dr. Lindberg is a PhD Student in translational metastatic breast cancer research, lecturer of Evidence-Based Medicine for medical students at Umeå University and recently started as a resident in anaesthesiology. She serves as Scientific Secretary of Swedish Medical Society for Medical Students and Junior Doctors, where she is responsible for awarding a national prize for the best scientific article by a medical student in Sweden. She has extensive experience organising extra-curricular initiatives that advocate for medical student involvement in research and education, including her current role leading the organisation of a national conference for medical students focused on inspiring research engagement.

Dr Luan Chen, PhD, MSc

Postdoctoral Fellow, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

Dr Luan Chen is a postdoctoral fellow at Xinhua Hospital, Shanghai Jiao Tong University School of Medicine. Dr Chen holds a PhD in Biology from Shanghai Jiao Tong University, an MSc in Bioinformatics and Computational Biology from Yale University, and a BSc in Statistics from the University of Minnesota. Dr Chen's research integrates statistical genetics, bioinformatics, clinical data science, and artificial intelligence to advance precision approaches in neurodevelopmental and psychiatric health. This work spans large-scale genomic analyses of autism, AI-enabled assessment and longitudinal phenotyping, and pharmacogenomic prediction of treatment response. Dr Chen has contributed first- and co-first-author research in Nucleic Acids Research and Molecular Psychiatry and is the first inventor on a patent application for predicting antipsychotic treatment suitability.

As an Early Career Researcher, Dr Chen brings the Commission a cross-disciplinary perspective grounded in rigorous quantitative methods, clinically relevant research, and evidence synthesis. A central interest is the responsible integration of genomic, behavioral, and digital data to improve early identification, stratification, and individualized care, with close attention to external validation, equity, and real-world implementation.

Dr Michele Nguyen PhD

Assistant Professor & Nanyang Technological University Singapore 

Dr. Michele Nguyen is an Assistant Professor of Data Analytics at the Lee Kong Chian School of Medicine, with a joint appointment at the School of Physical and Mathematical Sciences at Nanyang Technological University and the National Centre for Infectious Diseases, Singapore. She serves as Co-Chair of Working Group 5 for the Lancet Commission on Precision Health, leading the global evaluation of the economic consequences of action versus inaction to support the timely, proportionate, and sustainable adoption of precision health interventions worldwide.

With a Ph.D. in Statistics from Imperial College London, Dr. Nguyen brings world-class methodological expertise in statistical modelling and machine learning. Her research successfully bridges environmental volatility, clinical risk, and healthcare operational logistics, enabling health systems to dynamically coordinate assets and absorb shocks during active crises. Her work is published in elite journals such as The Lancet and Nature Sustainability, and her predictive models directly inform landmark global policy frameworks, including the World Health Organization’s World Malaria Report and the United Nations' Global Assessment Report on Disaster Risk Reduction.

As an Academic Editor for PLOS Global Public Health, Dr. Nguyen is deeply committed to advancing equity in global health. Her rare ability to translate complex predictive analytics into highly actionable, economically viable healthcare strategies makes her a major asset to the Commission, ensuring it delivers the robust, data-driven frameworks necessary to convince global decision-makers to scale precision health equitably and accessibly.

Shi Zhang, MMedSc

PhD Candidate & Faculty of Medicine, Lund University 

As a PhD student with training in cardiometabolic precision medicine, I contribute to the Commission’s evidence synthesis work, with a particular focus on cardiometabolic diseases and AI-assisted systematic reviews. My work includes independent human screening of cardiometabolic literature in Tier 1, providing a reference standard for evaluating AI-assisted screening, as well as contributing to the design of an AI agent–enabled systematic review workflow for Tier 2. Through this work, I bring experience in evidence synthesis and the application of emerging AI approaches to support rigorous and scalable precision health research.

Assist. Prof/Dr. Linda M. Bojmar, PhD

Assistant Professor & Linköping University/Weill Cornell Medicine 

Assistant Professor Linda Bojmar is a translational cancer researcher who’s work spans from basic science to clinical trials. Dr. Bojmar focus is on hard-to-treat malignancies, primarily pancreatic cancer, but also other tumors of the gastrointestinal tract with common hepatic metastasis. Dr. Bojmar also studies rare and aggressive pediatric tumors with metastatic propensity. Dr. Bojmar apply state-of-the-art multiomic-based approaches on tissue- and liquid biopsies to obtain a holistic understanding of human disease from a host perspective. Mechanistic studies of the metastatic process are combined with unique human data, into precision prediction models and ultimately forms the basis of future virtual human twins. The overall aim with Dr. Bojmar’s research is to tailor treatment based on the holistic understanding of each patient, while also improving our knowledge on metastatic disease. 

Dr. Bojmar published the first human atlas of the “pre-metastatic liver” in pancreatic cancer patients during her postdoctoral training with Prof. David Lyden at Weill Cornell Medicine, together with Memorial Sloan Kettering Cancer Center (Bojmar et al., Nature Medicine 2024). Her current work explores the transferability of such data from an American patient population to Swedish patients. Collaborative work with South Korea further broadens the applicability of her studies. In 2026, Dr. Bojmar received and ERC Starting Grant to start a randomized control trial to test the clinical value of her holistic prediction model. Dr. Bojmar is a board member of the Swedish Study Group for Pancreatic Cancer Research (SSPAC) and the Swedish Tumor Microenvironment Network (STorM) and she works closely with the Systems Biology Group at Linköping University (including the M4-Health Network) and the Swedish patient organization for hepatopancreatobiliary cancers (PALEMA) towards clinical implementation.  

Dr. Anna Stubbendorff

Post Doc, Lund University, Sweden

Dr Anna Stubbendorff is a postdoctoral researcher at Lund University and a registered dietitian working at the intersection of nutritional epidemiology, public health, and planetary health. She has helped shape the field of sustainable diets by integrating environmental impacts with nutritional adequacy and long-term health outcomes. Her research has advanced understanding of how adherence to the planetary health diet and dietary greenhouse gas emissions relate to nutritional status, disease risk, and mortality, identifying opportunities and trade-offs in aligning dietary recommendations with human and planetary health. Through Lund University’s interdisciplinary Agenda 2030 Graduate School, she has further developed expertise in connecting health research with environmental science and sustainable development.

Dr Stubbendorff co-coordinates EPIC-Shift, an EU Horizon Europe project supporting the transition towards healthier and more sustainable food systems. She also co-coordinates research on iron deficiency and health behaviours among adolescent girls, integrating dietary, biological, and behavioural perspectives to inform targeted interventions. She combines expertise in dietary assessment, population-based research, and clinical dietetics with experience in interdisciplinary research coordination and a background in media and communication. Her distinctive contribution to the Commission is connecting individual nutritional needs with the behavioural, social, and environmental conditions that determine whether recommendations can be put into practice. Drawing on this expertise, she will help bridge personalised prevention and public health, supporting targeted nutritional strategies that benefit individuals and populations while remaining equitable and environmentally sustainable.

Manya Gupta 

Economics and Global Health Undergraduate Student at Harvard University 

Manya has been leading research with Dr. Stéphane Verguet in Working Group 5 of the Lancet Commission for Precision Health. She primarily focuses on the creation of an extended cost-effectiveness model designed to evaluate the health benefits and economic viability of precision health interventions. She collaborates with several Working Group 5 colleagues to adapt the model to different populations and countries. In addition, Manya serves as a member of the precision health umbrella review team.  

Sydney Gough

Masters Student at King’s College London in Global Health, Social Justice & Public Policy

My recent studies in Global Health, Social Justice, and Public Policy along with Bachelors degrees in Biology and Political Science allow for an intersectional approach to precision health. In my MSc program, my research has focused primarily on global health governance, structural inequalities, and whose health needs are prioritized. This perspective allows me to contribute to the Commission’s consideration of equitable implementation of precision health across different systems.

Luis M Coral, MD, MsC

PhD Student, Lund University  

Within the Commission, I work as co-lead of Working Group 3 (Data Analytics and Translational Research), I contribute execution of analytical pipelines at the intersection of clinical medicine, epidemiology, machine learning, and precision health implementation.

My research centres on predictive subgrouping approaches, quantifying uncertainty, validating findings across populations, and assessing whether analytical advances translate into meaningful improvements in care. My interest revolves around disease heterogeneity, empowering validated analytical findings towards equitable implementation and prospective testing.

Anders Kämpe, MD, PhD

Resident doctor at Clinical Genetics and Genomics, Karolinska University Hospital, and researcher at Karolinska Institutet, Stockholm Sweden.

Anders Kämpe is a physician-scientist at Karolinska Institutet and a clinically active physician at the Department of Clinical Genetics and Genomics, Karolinska University Hospital. His research focuses on the genetics of severe mental disorders and the translation of genomic discoveries into clinically meaningful precision-health approaches. During his postdoctoral training at the Institute for Molecular Medicine Finland, he investigated the genetic architecture of psychotic disorders using large-scale resources including the SUPER-Finland Study and national biobank FinnGen. His work integrates common and rare genetic variation with longitudinal clinical and registry data, combining computational genomics with a direct understanding of patient care. He has also contributed to international recommendations for defining treatment outcomes in major psychiatric disorders using real-world data. 

Within the Lancet Commission on Precision Health, Anders brings expertise from mental health—one of the areas in which precision health remains least developed and where the gap between research and clinical implementation is particularly pronounced. His clinical work gives him first-hand insight into what is required to translate data, genomic findings, and AI-supported tools into safe and useful care, interoperable data systems, workable clinical pathways, trained personnel and patient trust. As a member of the executive committee of the Precision Omics Initiative Sweden, he also contributes experience of national collaboration and capacity building. Through Working Group 2, he aims to help develop infrastructure and access recommendations that are clinically practicable, equitable, and applicable across diverse health systems. 

Dr. Raymond J. Kreienkamp, MD, PhD

Attending in Endocrinology, Boston Children’s Hospital; Associate Member, Broad Institute of MIT and Harvard; Instructor, Harvard Medical School 

Dr. Kreienkamp is a physician-scientist and pediatric endocrinologist at Boston Children’s Hospital, where he is Director of the Boston Children’s Hospital Diabetes Genetics Clinic. He is interested in the use of genetics to improve the care of individuals with diabetes, specifically to ensure that each individual diagnosed with diabetes receives the correct diagnosis and is treated with the optimal therapy for their disease. 

Dr. Kreienkamp has published and spoken widely on this topic. He has demonstrated that current clinical tools perform poorly at recognizing MODY in youth thought to have type 2 diabetes. He has published on strategies to improve MODY identification in pediatric diabetes clinics. He has also demonstrated the possible utility of type 1 polygenic scores to improve diagnostic accuracy in pediatric diabetes care. Other work has included the identification of clusters in youth-onset type 2 diabetes, as well as contributions to a novel multi-ancestry type 1 diabetes polygenic score. He is active member of multiple consortium advancing precision medicine in diabetes care, including the Rare and Atypical Diabetes Network (RADIANT) and Precision Diabetes Consortium (PREDICT). He is excited to contribute to the Lancet Commission on Precision Health.